BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 35264616)

  • 1. A comprehensive systematic review and network meta-analysis: the role of anti-angiogenic agents in advanced epithelial ovarian cancer.
    Helali AE; Wong CHL; Choi HCW; Chan WWL; Dickson N; Siu SWK; Chan KK; Ngan HYS; Ngan RKC; Kennedy RD
    Sci Rep; 2022 Mar; 12(1):3803. PubMed ID: 35264616
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Luteinising hormone releasing hormone (LHRH) agonists for the treatment of relapsed epithelial ovarian cancer.
    Wuntakal R; Seshadri S; Montes A; Lane G
    Cochrane Database Syst Rev; 2016 Jun; 2016(6):CD011322. PubMed ID: 27356090
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy of trebananib (AMG 386) in treating epithelial ovarian cancer.
    Al Wadi K; Ghatage P
    Expert Opin Pharmacother; 2016; 17(6):853-60. PubMed ID: 26933765
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical guidelines for ovarian cancer: the Korean Society of Gynecologic Oncology guidelines.
    Lee B; Chang SJ; Kwon BS; Son JH; Lim MC; Kim YH; Lee SW; Choi CH; Eoh KJ; Lee JY; Suh DH; Kim YB
    J Gynecol Oncol; 2024 Jan; 35(1):e43. PubMed ID: 38178704
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Survival and prognostic factors in patients with recurrent low-grade epithelial ovarian cancer: An analysis of five prospective phase II/III trials of NOGGO metadata base.
    Canaz E; Grabowski JP; Richter R; Braicu EI; Chekerov R; Sehouli J
    Gynecol Oncol; 2019 Sep; 154(3):539-546. PubMed ID: 31230821
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inflammatory indexes as predictive factors for platinum sensitivity and as prognostic factors in recurrent epithelial ovarian cancer patients: a MITO24 retrospective study.
    Farolfi A; Scarpi E; Greco F; Bergamini A; Longo L; Pignata S; Casanova C; Cormio G; Bologna A; Orditura M; Zavallone L; Attademo L; Gallà V; Franzese E; Pigozzi E; Loizzi V; Giorda G; Giardina D; Cioffi R; De Giorgi U
    Sci Rep; 2020 Oct; 10(1):18190. PubMed ID: 33097745
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Novel treatment options in platinum-sensitive recurrent ovarian cancer: A review.
    Mullen MM; Kuroki LM; Thaker PH
    Gynecol Oncol; 2019 Feb; 152(2):416-425. PubMed ID: 30409489
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Chemotherapeutic Regimens and Chemotherapy-Free Intervals Influence the Survival of Patients with Recurrent Advanced Epithelial Ovarian Carcinoma: A Retrospective Population-Based Study.
    Huang HY; Chiang CJ; Chen YY; You SL; Hsu HC; Tang CH; Cheng WF
    Int J Environ Res Public Health; 2021 Jun; 18(12):. PubMed ID: 34202996
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The efficacy and toxicity of angiogenesis inhibitors for ovarian cancer: a meta-analysis of randomized controlled trials.
    Guo C; Yan C; Qu L; Du R; Lin J
    Arch Gynecol Obstet; 2021 Feb; 303(2):285-311. PubMed ID: 33222040
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Poly(ADP-ribose) polymerase (PARP) inhibitors for the treatment of ovarian cancer.
    Wiggans AJ; Cass GK; Bryant A; Lawrie TA; Morrison J
    Cochrane Database Syst Rev; 2015 May; 2015(5):CD007929. PubMed ID: 25991068
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Is ovarian cancer a targetable disease? A systematic review and meta-analysis and genomic data investigation.
    Staropoli N; Ciliberto D; Chiellino S; Caglioti F; Giudice TD; Gualtieri S; Salvino A; Strangio A; Botta C; Pignata S; Tassone P; Tagliaferri P
    Oncotarget; 2016 Dec; 7(50):82741-82756. PubMed ID: 27764790
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bevacizumab in recurrent ovarian cancer.
    Sait Bakir M; Birge O; Karadag C; Ilhan Y; Aykut Tuncer H; Sezgin Göksu S; Simsek T
    J BUON; 2021; 26(4):1271-1278. PubMed ID: 34564981
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical Trials of Novel Targeted Therapies in Ovarian Cancer: Moving Beyond Poly ADP Ribose Polymerase (PARP) Inhibitors.
    Guo Q; Yang Q; Li J; Liu G; Nikoulin I; Jia S
    Curr Pharm Biotechnol; 2018; 19(14):1114-1121. PubMed ID: 30585545
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Addition of bevacizumab to chemotherapy in patients with ovarian cancer: a systematic review and meta-analysis of randomized trials.
    Li J; Zhou L; Chen X; Ba Y
    Clin Transl Oncol; 2015 Sep; 17(9):673-83. PubMed ID: 25990506
    [TBL] [Abstract][Full Text] [Related]  

  • 15. ToleRability of BevacizUmab in elderly Ovarian cancer patients (TURBO study): a case-control study of a real-life experience.
    Amadio G; Marchetti C; Villani ER; Fusco D; Stollagli F; Bottoni C; Distefano M; Colloca G; Scambia G; Fagotti A
    J Gynecol Oncol; 2020 Jan; 31(1):e6. PubMed ID: 31788996
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Integrating bevacizumab into the management of epithelial ovarian cancer: the controversy of front-line versus recurrent disease.
    Monk BJ; Pujade-Lauraine E; Burger RA
    Ann Oncol; 2013 Dec; 24 Suppl 10():x53-x58. PubMed ID: 24265406
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and toxicity of bevacizumab in recurrent ovarian disease: an update meta-analysis on phase III trials.
    Marchetti C; De Felice F; Palaia I; Musella A; Di Donato V; Gasparri ML; Musio D; Muzii L; Tombolini V; Panici PB
    Oncotarget; 2016 Mar; 7(11):13221-7. PubMed ID: 26657509
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The use of bevacizumab in the modern era of targeted therapy for ovarian cancer: A systematic review and meta-analysis.
    Liu S; Kasherman L; Fazelzad R; Wang L; Bouchard-Fortier G; Lheureux S; Krzyzanowska MK
    Gynecol Oncol; 2021 May; 161(2):601-612. PubMed ID: 33546867
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Quality of life in patients with advanced epithelial ovarian cancer (EOC) randomized to maintenance pazopanib or placebo after first-line chemotherapy in the AGO-OVAR 16 trial. Measuring what matters-patient-centered end points in trials of maintenance therapy.
    Friedlander M; Rau J; Lee CK; Meier W; Lesoin A; Kim JW; Poveda A; Buck M; Scambia G; Shimada M; Hilpert F; King MT; Debruyne P; Bologna A; Malander S; Monk BJ; Petru E; Calvert P; Herzog TJ; Barrett C; du Bois A
    Ann Oncol; 2018 Mar; 29(3):737-743. PubMed ID: 29267856
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Angiogenesis inhibitors for patients with ovarian cancer: a meta-analysis of 12 randomized controlled trials.
    Li X; Zhu S; Hong C; Cai H
    Curr Med Res Opin; 2016; 32(3):555-62. PubMed ID: 26652645
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.